Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2021

View Archived Issues

Anti-PD-L1 IGM-7354 shows promise for cancer immunotherapy

Rat model for PD using AAV-induced overexpression of E46K-like alphaSYN mutants

Antibody-drug conjugate SGN-B7H4V shows promise in preclinical models of cancer

SGN-PDL1V, a PD-L1-directed ADC with activity in multiple tumor xenograft models

Hangzhou Innogate Pharma divulges SYK and JAK2 kinase inhibitors

Betta Pharmaceuticals patents new compounds for cancer

Beijing Tide Pharmaceutical identifies GTPase KRAS inhibitors

Chinese researchers synthesize new phosphodiesterase PDE4 inhibitors

Biopolar Hongye (Nantong) Pharmaceutical synthesizes JAK2 inhibitors

Bexson expands ketamine patch pump program into depression

Discovery of novel APJ receptor agonist with promising activity in acute hemodynamic rat model

A-2342: a highly potent, selective, orally available NTCP inhibitor

Artizan and Biohaven begin therapeutic discovery and development program in Parkinson's

Researchers develop new model of heart failure with preserved ejection fraction

p21-controlled immunoclearance mechanism identified in senescent cells

Replication stress response defects signature predicts ICB response in nonhypermutated cancers

Study offers insights into post-MI fibrosis

Zika virus antagonism of mitophagy drives pathological proinflammatory chemokine expression

FAUST, a novel interpretable machine-learning method for unbiased discovery in single-cell cytometry

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...